Case Report
Pulmonary arterial hypertension due to pulmonary vascular amyloid deposition in a patient with multiple myeloma

Hirotugu Hashimoto1,2, Atsushi Kurata2, Hideaki Mizuno2, Tamaki Nashiro1, Akira Hangaishi2, Masahiko Kuroda2, Kensuke Usuki3, Hajime Horiuchi1

1Department of Diagnostic Pathology, NTT Medical Center Tokyo, Tokyo, Japan; 2Department of Molecular Pathology, Tokyo Medical University, Tokyo, Japan; 3Department of Hematology, NTT Medical Center Tokyo, Tokyo, Japan

Received September 27, 2015; Accepted October 27, 2015; Epub November 1, 2015; Published November 15, 2015

Abstract: Systemic amyloidosis is characterized by amyloid deposition throughout the body and subsequent dysfunction of various organs. Although pulmonary amyloidosis does occur, pulmonary hypertension (PH) caused by amyloidosis is extremely rare. In most of these cases, amyloid deposition occurred diffusely in alveolar septa, indicating that PH was due to lung disease and/or hypoxia. On the other hand, the mechanism of PH due to amyloid deposition in the pulmonary arteries has never been demonstrated. Here, we report the first case of PH due to amyloid deposition in pulmonary elastic arteries and muscular artery, which was complicated by multiple myeloma (MM). In the autopsy specimen of the patient, amyloid deposition was found mainly in the pulmonary arterial media, along with intimal thickening with luminal narrowing. PH thus appeared to be caused by marked decrease of pulmonary elasticity due to the amyloid deposition in the arterial media that resulted in stasis of the blood flow and subsequent luminal narrowing. Our present data demonstrates a new concept of PH caused by amyloidosis, namely, pulmonary arterial hypertension due to amyloidosis.

Keywords: AL amyloidosis, pulmonary arterial hypertension, multiple myeloma, pulmonary artery

Introduction

Systemic amyloidosis is caused by the deposition of amyloid in various organs, subsequently causing their dysfunction. However, pulmonary dysfunction due to amyloid deposition in the lungs is rare [1, 2], and in particular, pulmonary hypertension (PH) caused by amyloidosis is an extremely rare condition; only 13 cases have been reported in the English literature to date (Table 1) [3-11]. In most of these cases, amyloid deposition was found diffusely in alveolar septa: amyloid deposition on the media of the pulmonary elastic and muscular arteries causing pulmonary arterial hypertension (PAH) has never been reported. Here, we present a first case of PAH due to pulmonary vascular amyloid deposition in a patient with multiple myeloma (MM), and demonstrate a new mechanism of PAH due to pulmonary amyloid deposition.

Clinical history

An 83-year-old woman was admitted to hospital owing to pneumonia. She had previously had pneumonia twice, at 74-years and 76-years of age. Her previous doctor suspected MM from her data of hypergammaglobulinemia, hypercalcemia, elevated serum creatinine level, and anemia. After treatment of the pneumonia, she was referred to our hospital. At admission, her serum hemoglobin level was 8.7 g/dL, calcium level corrected by her albumin level was 9.8 mg/dL, creatinine level was 1.50 mg/dL, and beta-2 microglobulin was 8.9 mg/dL (normal: 0.9-1.9). Her total protein level was high at 9.5 g/dL, and the M protein was observed by analysis of the protein fraction, and immunoelectrophoresis revealed immunoglobulin (Ig) G-k type. X-ray photography displayed multiple punched-out lesions in her bones. Thirty-four percent of
the nucleated cells in her bone marrow aspira-
tion material were monoclonal plasmacytoid cells. These data led to a diagnosis of stage III
MM according to the International Staging
System.

After the diagnosis, the patient was treated
with chemotherapy. At the beginning of chemo-
therapy, her right ventricular pressure estimat-
ed by cardiac echography was 39 mmHg, show-
ing slight high pressure; however no other
cardiac dysfunction was observed. Initially, the patient was treated with 5 courses of melpha-
lan-prednisolone therapy. Although stable dis-
ease was obtained, severe myelosuppression
terminated the therapy. Thereafter, she was
treated with lenalidomide-dexamethasone (Rd)
therapy, high-dose dexamethasone therapy,
combination therapy of bortezomib and dexam-
ethasone, and combination therapy of cyclo-
phosphamide, vincristine, and dacarbazine for
2 years and 5 months. Severe side effects or
restricted therapeutic effects resulted in the
changes in treatment regimens. The patient
was then re-admitted because of severe myelo-
suppression and a worsened state of MM. She
was treated by Rd therapy, which was highly
effective despite her past history of severe side
effects.

At this time, her cardiac echography demon-
strated an ejection fraction of 79%, indicating
normal left ventricular contractile activity, along
with normal left ventricular expansion ability.

However, her estimated right ventricular pres-
sure was 60 mmHg, suggesting PH (Figure 1).
Further investigation for PH was difficult
because of her poor general state. The patient’s
advanced status of MM, decreased blood pres-
sure, and renal dysfunction worsened her gen-
eral status, and she died 1 month after the last
admission. Subsequently, an autopsy was
performed.

Autopsy findings

At autopsy, multiple osteolytic lesions contain-
ing massive plasmacytoid cells were found in
the patient’s ileum, ribs, and vertebrae. Immunohistochemical analysis showed that the plasmacytoid cells were positive for CD138. Furthermore, polymerase chain reaction analy-
sis of the genome of these plasmacytoid cells,
to amplify the complementarity determining 3
region of the Ig heavy chain showed a monoclo-
nal band upon electrophoresis, revealing that
they were residual myeloma cells. In addition,
the deposition of amorphous eosinophilic mate-
rial was found in systemic blood vessels, mainly
in the vascular media of elastic arteries and
relatively thick muscular arteries (outer media
> 100 μm). The deposition of eosinophilic mate-
rial was also seen in muscles, mainly smooth
muscles of multiple organs. These materials
were stained with the direct fast scarlet stain,
and double refraction was confirmed by polar-
ization, which indicated amyloid deposition.
Immunohistochemical analysis showed that

### Table 1. Previous reports of cases of pulmonary hypertension with amyloidosis

<table>
<thead>
<tr>
<th>Case</th>
<th>Author (year)</th>
<th>Age (sex)</th>
<th>Pattern of pulmonary amyloid deposition (method of detection)</th>
<th>PAP (mmHg)</th>
<th>Amyloidosis type</th>
<th>MM</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Shiue ST, et al (3) (1988)</td>
<td>65 (F)</td>
<td>Diffuse vascular deposition with little in alveolar capillaries (open lung biopsy)</td>
<td>39</td>
<td>AL (+)</td>
<td>MM</td>
</tr>
<tr>
<td>5</td>
<td>Dingl D, et al (7) (2001)</td>
<td>61 (F)</td>
<td>ND</td>
<td>58</td>
<td>AL (--)</td>
<td>MM</td>
</tr>
<tr>
<td>6</td>
<td>Dingl D, et al (7) (2001)</td>
<td>64 (F)</td>
<td>ND</td>
<td>36 (*)</td>
<td>AL (--)</td>
<td>MM</td>
</tr>
<tr>
<td>7</td>
<td>Dingl D, et al (7) (2001)</td>
<td>82 (M)</td>
<td>ND</td>
<td>76 (*)</td>
<td>AL (--)</td>
<td>MM</td>
</tr>
<tr>
<td>14</td>
<td>Present case (2015)</td>
<td>85 (F)</td>
<td>Pulmonary vascular deposition with little in alveolar capillaries (autopsy)</td>
<td>60 (*)</td>
<td>AL (--)</td>
<td>MM</td>
</tr>
</tbody>
</table>

PAP: pulmonary arterial pressure, ND: not described, FMF: familial Mediterranean fever, β2M: beta-2 microglobulin, MM: multiple myeloma. (*) Estimated by echocar-
diography.
these amyloid deposits were positive for amyloid P component, IgG, and Igκ, and negative for amyloid A component, Igλ, beta-2 microglobulin, and transthyretin. Thus, the patient was also diagnosed as having systemic amyloid light chain (AL) amyloidosis.

The pulmonary arteries in the pulmonary hilar region were dilated, and her right ventricle was also slightly dilated, which was compatible with PH. Furthermore, amyloid deposition was also found in the pulmonary arteries and veins; in the pulmonary elastic arteries, amyloid depo-

Figure 1. Antemortem cardiac echography. Echocardiography demonstrated that the pressure gap between the right atrium and right ventricle estimated by the speed of tricuspid regurgitation was 55 mmHg, suggesting pulmonary hypertension.

Figure 2. Pulmonary hilar elastic arteries. A. Direct fast scarlet staining of pulmonary hila demonstrated amyloid deposition in the pulmonary elastic arterial media and muscular arterial wall without alveolar involvement. B. Elastica-Masson staining of the pulmonary arteries demonstrated that the patient’s medial elastic fibers were torn by amyloid deposition.
tion was seen on the vascular walls, mainly on the media (Figure 2A), along with torn medial elastic fibers (Figure 2B). Amyloid deposition was also observed in the relatively thick muscular arteries and veins (thicker than interlobular veins). In muscular arteries, amyloid diffusely deposited on medial muscles (Figure 3A), accompanied by intimal thickening with luminal narrowing (Figure 3B). Furthermore, recanalization of organized thrombus was partially observed (Figure 3C). But amyloid deposition was rarely detected in the thin vessels, capillary or alveolar septa. Plexiform lesions, fibrinoid necrosis, and vasculitis were not identified.

The cause of the renal dysfunction was concluded to be myeloma kidney and decreased blood flow caused by amyloidosis in the kidneys without deposition in the glomeruli.

The patient's cause of death was considered to be a worsened general status caused by the MM, as well as amyloidosis that caused the PH and renal dysfunction.

Discussion

We presented a case of a patient with MM accompanying systemic AL amyloidosis and PH. The unique finding of this case was the pattern of pulmonary amyloid deposition. Pulmonary amyloid deposition has been classified into 3 main types: nodular lesion, tracheobronchial deposition, and diffuse alveolar septal deposition [12]. The present case lacked all these 3 patterns. Instead, amyloid deposition in the media of the elastic and muscular pulmonary arteries was found.

PH is generally classified into different groups by their mechanism, and most of the reported 13 cases of PH associated with systemic amyloidosis, with amyloid deposition in alveolar septa, would be classified into the group of PH due to lung disease and/or hypoxia [13]. On the other hand, the present case should be classified into the group of PAH, which has never been reported in association with pulmonary amyloidosis. The mechanism of PAH was thought to be attributed to marked decrease in pulmonary elasticity due to the destruction of pulmonary medial elastic fibers and muscles by amyloid deposition, leading to stasis of the blood flow, subsequently causing thrombus with recanalization or luminal narrowing. Luminal narrowing is one of the most important factors presented by Poiseulle equation of flow rate [14]. Other diseases that cause PH, such as idiopathic PAH, left ventricular systolic or diastolic dysfunction, and lung disease were excluded by antemortem echography or autopsy findings.
The first case of PH caused by amyloidosis was reported in 1988, in which the patient was originally diagnosed with MM [3]. In this patient, amyloid deposition in the muscular arterial wall and in a few alveolar septa was demonstrated by open lung biopsy. The authors hypothesized that MM-associated amyloidosis causing PH might have different characteristics to the other types of amyloidosis. However, amyloid distribution could not be investigated as post-mortem examinations were not performed. Since then, 4 additional cases of PH with amyloidosis in patients with MM have been reported [7, 9, 10], but autopsy findings have not been described so far (Table 1).

Here, we present the first case of PAH due to amyloidosis, and demonstrate a new mechanism of PH caused by amyloidosis. The findings of this case shed light on a new concept of pulmonary amyloidosis.

Acknowledgements

We would like to thank Dr. Kei Hara for his academic advice, and Asako Shindo, Yoshiko Miyazaki, Goichiro Yanagi, and the clinical technologists of NTT Medical Center Tokyo for their technical assistance.

Disclosure of conflict of interest

None.

Address correspondence to: Dr. Hirotsugu Hashimoto, Department of Diagnostic Pathology, NTT Medical Center Tokyo, 5-9-22 Higashi-Gotanda, Shinagawa-ku, Tokyo 141-8625, Japan. Tel: +81 3 3448 6431; Fax: +81 3 3448 6434; E-mail: hhashimoto-tnki@umin.ac.jp

References